Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | MMP12 | P39900 | 3/20 | 0.53 |
| ▸ | MMP13 | P45452 | 3/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | MMP14 | P50281 | 1/20 | 0.53 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.44 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.44 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | CPA1 | P15085 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10015434 | 0.85 | KMT2A (0.66) | KMT2ADPP4FOLH1PTGER1PTGER4 | |
| SCHEMBL7520962 | 0.84 | KMT2A (0.57) | KMT2AMMP12MMP13MMP2MMP9 | |
| SCHEMBL289163 | 0.81 | KMT2A (0.62) | KMT2AMMP12MMP13MMP2MMP9 | |
| SCHEMBL13212054 | 0.79 | KMT2A (0.58) | KMT2ADPP4FOLH1PTGER1PTGER4 | |
| SCHEMBL2865284 | 0.79 | KMT2A (0.58) | KMT2AMMP12MMP13MMP2MMP9 | |
| SCHEMBL9148917 | 0.78 | KMT2A (1.00) | KMT2ADPP4FOLH1PTGER1PTGER4 | |
| SCHEMBL8550181 | 0.77 | MMP12 (0.46) | KMT2AMMP12MMP13MMP2MMP9 | |
| SCHEMBL16559378 | 0.76 | KMT2A (0.54) | KMT2ADPP4FOLH1PTGER1PTGER4 | |
| SCHEMBL2855436 | 0.76 | KMT2A (0.54) | KMT2AMMP12MMP13MMP2MMP9 | |
| SCHEMBL2864081 | 0.76 | KMT2A (0.54) | KMT2ADPP4FOLH1PTGER1PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846910-B2 | Matrix metalloproteinase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2014-09-30 | — | — | US | disclosed |
| US-8816073-B2 | Matrix metalloproteinase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2014-08-26 | — | — | US | disclosed |
| US-8710261-B2 | 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases | RANBAXY LABORATORIES LIMITED (IN) | 2014-04-29 | — | — | US | disclosed |
| US-20130302378-A1 | MATRIX METALLOPROTEINASE INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2013-11-14 | — | — | US | disclosed |
| US-20130295141-A1 | MATRIX METALLOPROTEINASE INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2013-11-07 | — | — | US | disclosed |
| US-8507670-B2 | Matrix metalloproteinase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2013-08-13 | — | — | US | disclosed |
| EP-2074093-B1 | PROCESS FOR PREPARING MATRIX METALLOPROTEINASE INHIBITORS AND CHIRAL AUXILIARY THEREFOR | RANBAXY LAB LTD (IN) | 2012-10-10 | — | — | EP | disclosed |
| EP-2474531-A2 | Matrix metalloproteinase inhibitors | Ranbaxy Laboratories Limited (IN) | 2012-07-11 | — | — | EP | disclosed |
| EP-1856063-B1 | 5-PHENYL-PENTANOIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FOR THE TREATMENT OF ASTHMA AND OTHER DISEASES | RANBAXY LAB LTD (IN) | 2012-01-25 | — | — | EP | disclosed |
| EP-2322507-A1 | Matrix metalloproteinase inhibitors | Ranbaxy Laboratories Limited (IN) | 2011-05-18 | — | — | EP | disclosed |
| US-20100081610-A1 | MATRIX METALLOPROTEINASE INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2010-04-01 | — | — | US | disclosed |
| EP-2074093-A2 | MATRIX METALLOPROTEINASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2009-07-01 | — | — | EP | disclosed |
| US-20080194565-A1 | 5-Phenyl-Pentanoic Acid Derivatives as Matrix Metalloproteinase Inhibitors for the Treatment of Asthma and Other Diseases | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2008-08-14 | — | — | US | disclosed |
| WO-2008023336-A2 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2008-02-28 | — | — | WO | disclosed |
| EP-1856063-A1 | 5-PHENYL-PENTANOIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FOR THE TREATMENT OF ASTHMA AND OTHER DISEASES | Ranbaxy Laboratories Limited (IN) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006090235-A1 | 5-PHENYL-PENTANOIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FOR THE TREATMENT OF ASTHMA AND OTHER DISEASES | RANBAXY LABORATORIES LIMITED (IN) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130302378-A1 | MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP8, MMP25 | KMT2A 2541/4885MMP12 5/4885MMP13 7/4885 |
| US-20130295141-A1 | MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP8, MMP25 | KMT2A 2541/4885MMP12 5/4885MMP13 7/4885 |
| US-20100081610-A1 | MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP8, MMP12 | KMT2A 2765/4885MMP12 3/4885MMP13 7/4885 |
| US-20080194565-A1 | 5-Phenyl-Pentanoic Acid Derivatives as Matrix Metalloproteinase Inhibitors for the Treatment of Asthma and Other Diseases | F2RL3, ACOX3, LPAR5 | KMT2A 4330/4885MMP12 15/4885MMP13 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.